<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04082260</url>
  </required_header>
  <id_info>
    <org_study_id>ProgramMS2017</org_study_id>
    <nct_id>NCT04082260</nct_id>
  </id_info>
  <brief_title>Signatures of Immune Reprogramming in Anti-CD52 Therapy of MS: Markers for Risk Stratification and Treatment Response</brief_title>
  <acronym>ProgramMS</acronym>
  <official_title>Signatures of Immune Reprogramming in Anti-CD52 Therapy of MS: Markers for Risk Stratification and Treatment Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Muenster</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Muenster</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Alemtuzumab is a highly effective therapy in relapse remitting multiple sclerosis (RRMS). The&#xD;
      aim of this study is to elucidate the mechanism of action of the neuroprotective potential of&#xD;
      alemtuzumab in RRMS. Therefore, the investigators will semi-annually analyse blood samples of&#xD;
      RRMS patients treated with alemtuzumab up to 36 months. Using in vitro/ ex vivo assays the&#xD;
      investigators aim to detect and characterize immune cells including their functional&#xD;
      activity. Furthermore, the study aims to combine this analysis with clinical data (MRI, EDSS:&#xD;
      Expanded Disability Status Scale, MSFC: Multiple Sclerosis Functional Composite) to reveal&#xD;
      the underlining mechanism of action of alemtuzumab to further improve its efficacy and safety&#xD;
      for present and future patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute and relative change of cell-counts compared to baseline of T cell subsets in the peripheral blood (every 6 months)</measure>
    <time_frame>36 month</time_frame>
    <description>• T cell subsets:&#xD;
CD (cluster of differentiation) 4 and CD8 positive T cells: naïve T cells, T effector cells, T memory cells, regulatory T cells&#xD;
T-helper subsets: Th1, Th2, Th17</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute and relative change of cell-counts compared to baseline of B-cell subsets in the peripheral blood (every 6 months)</measure>
    <time_frame>36 month</time_frame>
    <description>• B cell subsets:&#xD;
Recent bone marrow emigrants, mature naïve, memory B cells&#xD;
Plasma cells</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute and relative change of cell-counts compared to baseline of natural killer cells in the peripheral blood (every 6 months)</measure>
    <time_frame>36 month</time_frame>
    <description>• Natural killer cells:&#xD;
CD56bright, CD56dim&#xD;
Natural killer T cells</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute and relative change of cell-counts compared to baseline of antigen-presenting cells in the peripheral blood (every 6 months)</measure>
    <time_frame>36 month</time_frame>
    <description>• Antigen-presenting cells:&#xD;
Dendritic cells: CD303+ plasmacytoid, CD11c+ and CD141+ myeloid dendritic cells&#xD;
Monocytes and macrophages</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute and relative change of cell-counts compared to baseline of myeloid-derived suppressor cells in the peripheral blood (every 6 months)</measure>
    <time_frame>36 month</time_frame>
    <description>• Myeloid-derived suppressor cells</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in levels of markers of autoimmunity (ANA, cANCA and pANCA) in the serum (every 6 months):</measure>
    <time_frame>36 month</time_frame>
    <description>- IFT (immunoflescence-test) of ANA, cANCA and pANCA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in levels of markers of autoimmunity (anti-dsDNA) in the serum (every 6 months):</measure>
    <time_frame>36 month</time_frame>
    <description>- RIA (radioimmunoassay) of anti-dsDNA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in levels of markers of autoimmunity (anti-TSH-Receptor) in the serum (every 6 months):</measure>
    <time_frame>36 month</time_frame>
    <description>- Levels of anti-TSH-Receptor (U/ml)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in levels of markers of autoimmunity(anti-TPO) in the serum (every 6 months):</measure>
    <time_frame>36 month</time_frame>
    <description>- Levels of anti-TPO (U/ml)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in levels of markers of autoimmunity (Rheumatoid factor) in the serum (every 6 months):</measure>
    <time_frame>36 month</time_frame>
    <description>- Levels of Rheumatoid factor (U/ml)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in levels of markers of autoimmunity (anti-CCP) in the serum (every 6 months):</measure>
    <time_frame>36 month</time_frame>
    <description>- Levels of anti-CCP (U/ml)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in levels of markers of autoimmunity (anti-GBM) in the serum (every 6 months):</measure>
    <time_frame>36 month</time_frame>
    <description>- Levels of anti-GBM (U/ml)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in levels of markers of autoimmunity (antiplatelet antibodies) in the serum (every 6 months):</measure>
    <time_frame>36 month</time_frame>
    <description>- Levels of antiplatelet antibodies (U/ml)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functional characterization of T-cells and B cells in the peripheral blood (every 6 months)</measure>
    <time_frame>36 month</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Clinical related data: Analysis of MRI scans</measure>
    <time_frame>36 month</time_frame>
    <description>- Number and location of lesions in MRI scans will be count</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinical related data: Evaluation of disease activity and manifestation (EDSS) in comparison to baseline (every 6 months)</measure>
    <time_frame>36 month</time_frame>
    <description>• Expanded Disability Status Scale (EDSS):&#xD;
Scoring will be performed using standard scoring test from www.neurostatus.net.&#xD;
EDSS is an ordinal clinical rating scale which ranges from 0 (normal neurologic examination) to 10 (death due to MS) in half-point increments. EDSS steps 1.0 to 4.5 refer to people with MS who are fully ambulatory, while EDSS steps 5.0 to 9.5 are defined by the impairment to ambulation.</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinical related data: Evaluation of disease activity and manifestation (MSFC) in comparison to baseline (every 6 months)</measure>
    <time_frame>36 month</time_frame>
    <description>• Multiple Sclerosis Functional Composite (MSFC):&#xD;
MSFC will be administered according to the MSFC manual of the National MS Society.&#xD;
In brief measurements on the impact of MS in three key clinical dimensions: leg function and ambulation, arm and hand function, and cognitive function are done. Raw scores in different measurement scales are transformed into standard comparable scores (z-scores) and an overall composite score is calculated.</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinical related data: Observation of relapse rates</measure>
    <time_frame>36 month</time_frame>
    <description>- Number and time of relapses will be counted</description>
  </other_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>De novo patients with alemtuzumab</arm_group_label>
    <description>De novo patients prior and after alemtuzumab treatment initiation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alemtuzumab treatment</arm_group_label>
    <description>Patients under alemtuzumab treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Extended alemtuzumab treatment</arm_group_label>
    <description>Patients requiring more than two alemtuzumab infusions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alemtuzumab Injection [Lemtrada]</intervention_name>
    <description>Administration of 2 courses of alemtuzumab at an interval of 1 year. Course 1: Intravenous infusion of 12 mg alemtuzumab per day on 5 consecutive days.&#xD;
Course 2: Intravenous infusion of 12 mg alemtuzumab per day on 3 consecutive days.</description>
    <arm_group_label>Alemtuzumab treatment</arm_group_label>
    <arm_group_label>De novo patients with alemtuzumab</arm_group_label>
    <arm_group_label>Extended alemtuzumab treatment</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The patient population will be patients with active RRMS, which will be rectruited in&#xD;
        multiple KKNMS (Kompetenznetz Multiple Sklerose) centres.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of MS according to the McDonald criteria 2010 and cranial MRI scan&#xD;
             demonstrating white matter lesions attributable to MS within 5 years before prior to&#xD;
             signing the informed consent form (ICF)&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Written informed consent to study participation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Medical, psychiatric, cognitive, or other conditions that, in the Investigator's&#xD;
             opinion, compromise the patient's ability to understand the patient information, to&#xD;
             give informed consent, or to complete the study&#xD;
&#xD;
          -  Any progressive form of MS&#xD;
&#xD;
          -  Any condition that serves as a contraindication for alemtuzumab treatment&#xD;
&#xD;
          -  Any disability acquired from trauma or another illness that could interfere with the&#xD;
             evaluation of disability due to MS&#xD;
&#xD;
          -  Major systemic disease or other illness that would, in the opinion of the&#xD;
             Investigator, compromise patient safety or interfere with the interpretation of study&#xD;
             results, e.g., current peptic ulcer disease or other conditions that may predispose to&#xD;
             hemorrhage&#xD;
&#xD;
          -  Significant autoimmune disease including but not limited to immune cytopenias,&#xD;
             rheumatoid arthritis, systemic lupus erythematosus, other connective tissue disorders,&#xD;
             vasculitis, inflammatory bowel disease, severe psoriasis&#xD;
&#xD;
          -  Inability to undergo MRI with gadolinium administration&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sven Meuth, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neurology with Institute of Translational Neurology, University Hospital Muenster</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tobias Ruck, Dr.med.</last_name>
    <email>tobias.ruck@ukmuenster.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Neurology</name>
      <address>
        <city>Münster</city>
        <state>NRW</state>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tobias Ruck</last_name>
      <email>tobias.ruck@ukmuenster.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 28, 2019</study_first_submitted>
  <study_first_submitted_qc>September 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2019</study_first_posted>
  <last_update_submitted>September 18, 2019</last_update_submitted>
  <last_update_submitted_qc>September 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alemtuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

